Information about the 2013 American Pain Society Annual Meeting

Article

News and updates about the 2013 American Pain Society Annual Meeting.

32nd Annual Scientific Meeting of the American Pain Society

May 8-11, 2013

New Orleans, LA

The 2013 APS annual meeting will be held at the Ernest N. Morial Convention Center in New Orleans, LA.

Planning your meeting

Download the 2013 APS annual meeting brochure to access a complete conference schedule, information about presenters and faculty, exhibitor information, news about satellite symposia and other events, and additional meeting highlights.

Access the complete collection of 2013 APS annual meeting session handouts. Access the handouts by browsing by day or by session type and clicking on the title of a session, then by clicking on the link to the PDF handout which appears beneath each speaker’s name in the faculty listing for that session.

It is recommended that attendees print out session handouts ahead of time and bring them to the meeting as the 2013 APS annual meeting is a paperless meeting and there are limited printing capabilities at the convention center.

A searchable collection of poster abstracts for the 2013 APS annual meeting is available online at the Journal of Pain website.

Exhibit and poster hours

Wednesday, May 8

4:30-6:00pm (opening reception with exhibits and posters)

Thursday, May 9

9:00-11:00am — exhibits open

9:30-11:00 — poster break

3:30-5:30pm — exhibits open

3:45-5:15pm — poster break

Friday, May 10

8:30-10:15am — exhibits open

8:45-10:45am — poster break

Click here to learn more about restaurants, nightclubs, historic sites and locations, and other things to do and see while you’re visiting New Orleans.

Preconference symposium

On Wednesday, May 8, the 2013 APS annual meeting will feature a preconference symposium titled “Complementary and Alternative Medicine: Roles in Chronic Pain Management & Research.” The APS says this event will “raise awareness of approaches and challenges” for Complementary and Alternative Medicine (CAM) researchers and explore “possible clinical applications for health care professionals.”

The symposium will also address “challenges and opportunities associated with current CAM research as it relates to chronic pain management in the field of medicine” and “encourage collaborations among pain clinicians and researchers in CAM practice and research.”

Click here to access a symposium schedule and overview, a roster of faculty and presenters, and registration information.

Opioid REMS Session

On Saturday, May 11, the 2013 APS annual meeting will feature a free, three-hour CE course that will “provide prescribers with information needed to effectively assess the pain patient, develop a treatment plan, assess for risk of opioid misuse, and plan for ongoing assessment of the patient.”

Created by the APS and the Collaborative for REMS Education, the information offered during “Risk Evaluation and Mitigation Strategies (REMS) for Extended-Release and Long-Acting Analgesic Opioids: Achieving Safe Use While Improving Patient Care” will improve attendees’ abilities to:

  • Appropriately assess pain patients for treatment with ER/LA opioids, and evaluate risks and potential benefits of ER/LA therapy, as well as possible misuse
  • Properly initiate therapy, modify dose, and discontinue use of ER/LA opioid analgesics, and apply accurate dosing and conversion techniques as well as appropriate discontinuation strategies.
  • Manage ongoing therapy with ER/LA opioid analgesics, and properly use evidence-based tools while assessing for adverse affects
  • Counsel patients and caregivers about the safe use of ER/LA opioid analgesics, including proper storage and disposal
  • Review/assess general and product-specific drug information concerning ER/LA opioid analgesics, and identify potential adverse affects of ER/LA opioids

Click here to learn more about opioid REMS, faculty and presenters, and CE information for this program.

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
Pediatric Hidradenitis Suppurativa Severity not Linked to Obesity
Rizankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.